GlassScriptPhysician profile
Rebecca Testi
NPI 1871153908
$1,932.10
in general payments reported to CMS, 2019-2025
20 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $541 · 2023: $853 · 2024: $239 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.19 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $382.68 | 2022-2023 | Besremi |
| Cti Biopharma Corp. | $265.79 | 2022-2023 | Vonjo |
| Incyte Corporation | $230.82 | 2023 | Jakafi |
| Novartis Pharmaceuticals Corporation | $126.74 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $116.21 | 2021-2022 | |
| Astellas Pharma US INC | $108.09 | 2023-2025 | Vyloy, Xospata, Cresemba |
| Daiichi Sankyo INC. | $91.74 | 2022-2023 | Injectafer |
| Alexion Pharmaceuticals, INC. | $86.68 | 2021-2022 | |
| Celgene Corporation | $80.70 | 2022-2025 | Reblozyl |
| Taiho Oncology, INC. | $66.87 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $66.37 | 2023-2024 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $65.96 | 2023-2024 | Iclusig, Hyqvia |
| Astrazeneca Pharmaceuticals LP | $48.18 | 2023 | Imfinzi |
| Amgen INC. | $44.71 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $43.07 | 2022-2023 | Imbruvica, Epkinly |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33.16 | 2024 | |
| Adaptive Biotechnologies Corporation | $24.86 | 2024 | Clonoseq |
| Janssen Scientific Affairs, LLC | $17.82 | 2024 | Erleada |
| Geron Corporation | $17.10 | 2025 | Rytelo |
| Blueprint Medicines Corporation | $14.55 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Testi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.